Superworth

LivaNova price to free cash flow LIVN

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Nov 2, 2026
29.8×
10-year median
51.9×
Against its 10-year history
24th
percentile: 0 is its lowest day, 100 its highest
10-year range
13.6× to 369×
Peer median
22.8×

LivaNova's price to free cash flow is 29.8× as of Nov 2, 2026.

That is below its ten-year median of 51.9×, lower than on 76% of days in the last ten years.

Over that time it ranged from 13.6× in Apr 2025 to 369× in Jun 2021.

The median for 6 medical device stocks of a similar size is 22.8×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far29.8×17.3×30.5×
202517.9×13.6×25.0×
202423.3×23.3×364×
2023329×43.7×330×
202249.8×36.5×68.5×
202157.0×52.2×369×
2020n/m a value too high to mean anything
2019189×39.2×217×
201852.8×48.3×118×
201747.7×34.8×52.5×

Against its peers

Companies in Medical - Devices nearest LivaNova's size, closest first, today.

CompanyPrice to free cash flow
LIVNLivaNova29.8×
ITGRInteger52.6×
TMDXTransMedics29.2×
CNMDCONMED10.5×
ZBHZimmer Biomet12.2×
DXCMDexCom22.7×
GEHCGE HealthCare Technologies22.8×
Peer median22.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on LivaNova

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.